4:16 PM ET
8-K
Licensing Deal
Biomarin Pharmaceutical Licensing Deal with Ascendis Pharma A/S
BioMarin entered into a definitive Settlement and License Agreement with Ascendis Pharma, granting Ascendis a non-exclusive worldwide license to certain patents for the commercialization of TransCon CNP (navepegritide). In exchange, BioMarin will receive royalties of 20% on net sales in the U.S. and 18% in the EU, Brazil, and South Korea through May 2030, while both parties agreed to dismiss all pending patent litigation.
- Counterparty
- Ascendis Pharma A/S
- Term
- through May 2030